The Oncologist family is saddened by the death of oncology pioneer and Pinedo Cancer Care Prize winner José Baselga. You can read Dr. Bruce A. Chabner's "Remembering José" in our journal

Congratulations to Alessio Cortellini, MD

Dr. Cortellini’s work in risks of immunotherapy treatment for patients with pre‐existing autoimmune disease earns him The Oncologist’sYoung Investigator Award. Read more about Dr. Cortellini and his research.





Biomarkers in Breast Carcinoma

Richard S.P. Huang, et al., The Oncologist

This article reports the current landscape of biomarkers in breast cancer, focusing on patients using comprehensive genomic profiling and PD‐L1 immunohistochemistry in addition to the previous standard of care diagnostics for hormone receptor and human epidermal receptor 2 identification. The relationship between different immunotherapy biomarkers in patients with triple‐negative breast cancer is examined.



Real-World PFS for ALK TKIs in ALK+ NSCLC Patients

Mohammad Jahanzeb, et al., The Oncologist

Patients with non-small cell lung cancer (NSCLC) characterized by ALK rearrangements may benefit from ALK tyrosine kinase inhibitor (TKI) therapies. This article summarizes the characteristics of patients with ALK+ advanced NSCLC treated with ALK TKI therapy, describes treatment pathways and duration for these patients, and examines real-world progression-free survival and treatment discontinuation for patients receiving first-line and second-line ALK TKI therapy overall and for the subgroups of patients with and without pre-existing brain metastasis at ALK TKI initiation.


Hepatitis C Virus Infection and Chemotherapy in Breast Cancer: A Retrospective Chart Analysis

Saptaparni Ghosh, et al., The Oncologist

Currently, there are no guidelines for chemotherapy administration in hepatitis C virus-positive patients with breast cancer. This article addresses the knowledge gap, comparing breast cancer patients with and without concurrent hepatitis C virus to determine level of tolerance to treatment.